<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01230593</url>
  </required_header>
  <id_info>
    <org_study_id>10-469</org_study_id>
    <nct_id>NCT01230593</nct_id>
  </id_info>
  <brief_title>Chalazion Conservative Treatment Trial</brief_title>
  <official_title>A 5-year Multicenter Prospective Randomized Trial Comparing Three Conservative Chalazion Treatments</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McMaster University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Edward-Elmhurst Health System</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>McMaster University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An eyelid stye, or chalazion, is the most common eyelid ailment, and is caused by the
      blockage of one of the oil secreting glands of the eyelid (meibomian glands). This leads to a
      typically painful, swollen, and red eyelid bump that lasts from days to weeks and months. The
      chalazion may cause tearing, pressure on the cornea, and irritation, all of which contribute
      to its morbidity. There are many anecdotal first line treatments for this condition,
      including warm compresses to the eyelid, topical antibiotics, topical steroids, topical
      combination antibiotic/steroid, and oral antibiotics. There have been no clinical trials to
      compare the efficacy of any of these conservative treatments. We wish to determine the most
      effective conservative medical treatment for chalazia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Complete Resolution</measure>
    <time_frame>4-6 weeks</time_frame>
    <description>Defined as number of patients with chalazion size regression of 100%</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Chalazion Size Difference Post-Treatment</measure>
    <time_frame>baseline and 4-6 weeks</time_frame>
    <description>Change of size of eyelid chalazion in millimeters from baseline to 4-6 weeks post-treatment</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Chalazion Unspecified Eye, Unspecified Eyelid</condition>
  <condition>Chalazion Left Eye, Unspecified Eyelid</condition>
  <condition>Chalazion Right Eye, Unspecified Eyelid</condition>
  <condition>Chalazion Both Eyes</condition>
  <arm_group>
    <arm_group_label>Hot Compress</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>&quot;Hot Compress&quot;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tobrex</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>&quot;Hot Compress&quot;, &quot;Tobrex Drops&quot;, &quot;Tobrex Ointment&quot;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tobradex</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>&quot;Hot Compress&quot;, &quot;Tobradex Drops&quot;, &quot;Tobradex Ointment&quot;</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hot Compress plus Tobramycin Drops and Ointment</intervention_name>
    <description>In addition to hot compress, Tobramycin drops will be given to the affected eye 3x/day, and Tobramycin ointment will be given at night before bed.</description>
    <arm_group_label>Tobrex</arm_group_label>
    <other_name>Aktob</other_name>
    <other_name>Tobralcon</other_name>
    <other_name>Tobrasol</other_name>
    <other_name>Tobramycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hot compress plus Tobramycin/Dexamethasone Drops and Ointment</intervention_name>
    <description>In addition to hot compress, Tobramycin/Dexamethasone drops will be given to the affected eye 3x/day, and Tobramycin/Dexamethasone ointment will be given at night before bed.</description>
    <arm_group_label>Tobradex</arm_group_label>
    <other_name>Tobramycin/dexamethasone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Hot Compresses</intervention_name>
    <description>Hot compresses 3x/day to eyelids</description>
    <arm_group_label>Hot Compress</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Patients age 18 and above

          -  Patient with a palpable chalazion on any eyelid

          -  Patients with multiple chalazia but only a single one on each lid

          -  Normal lid anatomy enabling lid eversion

        Exclusion Criteria

          -  Patients with chalazia with atypical features (recurring chalazion, abnormal
             surrounding lid tissue, associated loss of lashes) that may indicate suspicion of
             malignancy

          -  Patients allergic to any agents being used in the study (tobramycin, dexamethasone)

          -  Patients who have had previous eyelid surgery to the same eyelid as the chalazion

          -  Patients under 18 years of age

          -  Patients without palpable lid chalazion

          -  Patients with multiple chalazia on one eyelid

          -  Patients with concurrent eyelid infection (cellulitis or conjunctivitis)

          -  Patients unable to give consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Albert Y Wu, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Elmhurst Hospital Center</name>
      <address>
        <city>Elmhurst</city>
        <state>New York</state>
        <zip>11373</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Hospital Eye Clinic</name>
      <address>
        <city>Stoney Creek</city>
        <state>Ontario</state>
        <zip>L8G 5E4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>October 27, 2010</study_first_submitted>
  <study_first_submitted_qc>October 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 29, 2010</study_first_posted>
  <results_first_submitted>April 4, 2017</results_first_submitted>
  <results_first_submitted_qc>June 9, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">June 12, 2018</results_first_posted>
  <last_update_submitted>June 9, 2018</last_update_submitted>
  <last_update_submitted_qc>June 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>McMaster University</investigator_affiliation>
    <investigator_full_name>Albert Wu</investigator_full_name>
    <investigator_title>M.D. Ph.D.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chalazion</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobramycin</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Hot Compress</title>
          <description>Patients in the hot compress arm will be shown how to apply hot compresses to the affected lid and gently massage the lid to encourage the chalazion to spontaneously drain for 5 minutes, 3x/day.
Hot Compresses: Hot compresses 3x/day to eyelids</description>
        </group>
        <group group_id="P2">
          <title>Hot Compress + Tobramycin Drops and Ointment</title>
          <description>In addition to using hot compress, patients in the Tobramycin arm will be prescribed Tobramycin drops 3x/day and ointment to be applied before bedtime.
Tobramycin Drops and Ointment: Tobramycin drops will be given to the affected eye 3x/day, and Tobramycin ointment will be given at night before bed.</description>
        </group>
        <group group_id="P3">
          <title>Hot Compress + Tobramycin/Dexamethasone Drops and Ointment</title>
          <description>In addition to using hot compress, patients in the Tobramycin/Dexamethasone arm will be prescribed Tobramycin/Dexamethasone drops 3x/day and ointment to be applied before bedtime.
Tobramycin/Dexamethasone Drops and Ointment: Tobramycin/Dexamethasone drops will be given to the affected eye 3x/day, and Tobramycin/Dexamethasone ointment will be given at night before bed.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="50"/>
                <participants group_id="P3" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="32"/>
                <participants group_id="P3" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Hot Compress</title>
          <description>Patients in the hot compress arm will be shown how to apply hot compresses to the affected lid and gently massage the lid to encourage the chalazion to spontaneously drain for 5 minutes, 3x/day.
Hot Compresses: Hot compresses 3x/day to eyelids</description>
        </group>
        <group group_id="B2">
          <title>Hot Compress + Tobramycin Drops and Ointment</title>
          <description>In addition to using hot compress, patients in the Tobramycin arm will be prescribed Tobramycin drops 3x/day and ointment to be applied before bedtime.
Tobramycin Drops and Ointment: Tobramycin drops will be given to the affected eye 3x/day, and Tobramycin ointment will be given at night before bed.</description>
        </group>
        <group group_id="B3">
          <title>Hot Compress + Tobramycin/Dexamethasone Drops and Ointment</title>
          <description>In addition to using hot compress, patients in the Tobramycin/Dexamethasone arm will be prescribed Tobramycin/Dexamethasone drops 3x/day and ointment to be applied before bedtime.
Tobramycin/Dexamethasone Drops and Ointment: Tobramycin/Dexamethasone drops will be given to the affected eye 3x/day, and Tobramycin/Dexamethasone ointment will be given at night before bed.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
            <count group_id="B2" value="50"/>
            <count group_id="B3" value="49"/>
            <count group_id="B4" value="149"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.50" spread="15"/>
                    <measurement group_id="B2" value="46.42" spread="19"/>
                    <measurement group_id="B3" value="47.52" spread="17"/>
                    <measurement group_id="B4" value="47.41" spread="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="79"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pre-treatment lesion duration (months)</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.55" spread="6"/>
                    <measurement group_id="B2" value="2.88" spread="3"/>
                    <measurement group_id="B3" value="5.72" spread="13"/>
                    <measurement group_id="B4" value="3.96" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Initial lesion size (mm)</title>
          <units>millimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.05" spread="3"/>
                    <measurement group_id="B2" value="6.16" spread="3"/>
                    <measurement group_id="B3" value="6.38" spread="3"/>
                    <measurement group_id="B4" value="6.19" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Complete Resolution</title>
        <description>Defined as number of patients with chalazion size regression of 100%</description>
        <time_frame>4-6 weeks</time_frame>
        <population>Intention to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Hot Compress</title>
            <description>Patients in the hot compress arm will be shown how to apply hot compresses to the affected lid and gently massage the lid to encourage the chalazion to spontaneously drain for 5 minutes, 3x/day.
Hot Compresses: Hot compresses 3x/day to eyelids</description>
          </group>
          <group group_id="O2">
            <title>Hot Compress + Tobramycin Drops and Ointment</title>
            <description>In addition to using hot compress, patients in the Tobramycin arm will be prescribed Tobramycin drops 3x/day and ointment to be applied before bedtime.
Tobramycin Drops and Ointment: Tobramycin drops will be given to the affected eye 3x/day, and Tobramycin ointment will be given at night before bed.</description>
          </group>
          <group group_id="O3">
            <title>Hot Compress + Tobramycin/Dexamethasone Drops and Ointment</title>
            <description>In addition to using hot compress, patients in the Tobramycin/Dexamethasone arm will be prescribed Tobramycin/Dexamethasone drops 3x/day and ointment to be applied before bedtime.
Tobramycin/Dexamethasone Drops and Ointment: Tobramycin/Dexamethasone drops will be given to the affected eye 3x/day, and Tobramycin/Dexamethasone ointment will be given at night before bed.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Complete Resolution</title>
          <description>Defined as number of patients with chalazion size regression of 100%</description>
          <population>Intention to treat population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Chalazion Size Difference Post-Treatment</title>
        <description>Change of size of eyelid chalazion in millimeters from baseline to 4-6 weeks post-treatment</description>
        <time_frame>baseline and 4-6 weeks</time_frame>
        <population>Intention to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Hot Compress</title>
            <description>Patients in the hot compress arm will be shown how to apply hot compresses to the affected lid and gently massage the lid to encourage the chalazion to spontaneously drain for 5 minutes, 3x/day.
Hot Compresses: Hot compresses 3x/day to eyelids</description>
          </group>
          <group group_id="O2">
            <title>Hot Compress + Tobramycin Drops and Ointment</title>
            <description>In addition to using hot compress, patients in the Tobramycin arm will be prescribed Tobramycin drops 3x/day and ointment to be applied before bedtime.
Tobramycin Drops and Ointment: Tobramycin drops will be given to the affected eye 3x/day, and Tobramycin ointment will be given at night before bed.</description>
          </group>
          <group group_id="O3">
            <title>Hot Compress + Tobramycin/Dexamethasone Drops and Ointment</title>
            <description>In addition to using hot compress, patients in the Tobramycin/Dexamethasone arm will be prescribed Tobramycin/Dexamethasone drops 3x/day and ointment to be applied before bedtime.
Tobramycin/Dexamethasone Drops and Ointment: Tobramycin/Dexamethasone drops will be given to the affected eye 3x/day, and Tobramycin/Dexamethasone ointment will be given at night before bed.</description>
          </group>
        </group_list>
        <measure>
          <title>Chalazion Size Difference Post-Treatment</title>
          <description>Change of size of eyelid chalazion in millimeters from baseline to 4-6 weeks post-treatment</description>
          <population>Intention to treat population</population>
          <units>millimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.20" spread="3"/>
                    <measurement group_id="O2" value="1.69" spread="3"/>
                    <measurement group_id="O3" value="1.54" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were monitored over a time frame of 4-6 weeks from baseline enrollment of each participant. Participants returned for follow-up between 4 and 6 weeks after starting treatment.</time_frame>
      <desc>Serious Adverse Events</desc>
      <group_list>
        <group group_id="E1">
          <title>Hot Compress</title>
          <description>Patients in the hot compress arm will be shown how to apply hot compresses to the affected lid and gently massage the lid to encourage the chalazion to spontaneously drain for 5 minutes, 3x/day.
Hot Compresses: Hot compresses 3x/day to eyelids</description>
        </group>
        <group group_id="E2">
          <title>Hot Compress, Tobrex Drops, Tobrex Ointment</title>
          <description>In addition to using hot compress, patients in the Tobramycin arm will be prescribed Tobramycin drops 3x/day and ointment to be applied before bedtime.
Tobramycin Drops and Ointment: Tobramycin drops will be given to the affected eye 3x/day, and Tobramycin ointment will be given at night before bed.</description>
        </group>
        <group group_id="E3">
          <title>Hot Compress, Tobradex Drops, Tobradex Ointment</title>
          <description>In addition to using hot compress, patients in the Tobramycin/Dexamethasone arm will be prescribed Tobramycin/Dexamethasone drops 3x/day and ointment to be applied before bedtime.
Tobramycin/Dexamethasone Drops and Ointment: Tobramycin/Dexamethasone drops will be given to the affected eye 3x/day, and Tobramycin/Dexamethasone ointment will be given at night before bed.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Large loss to follow-up - only 70% completed follow-up - was a limitation.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Albert Wu MD PhD</name_or_title>
      <organization>Icahn School of Medicine at Mount Sinai</organization>
      <phone>2125184524</phone>
      <email>albert.wu@mssm.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

